S1:04 Enpatoran, a toll-like receptor 7/8 inhibitor, in skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: pooled safety data from the phase 2 willow trial

Objectives Fatigue, a debilitating symptom, is the most common symptom reported among patients with systemic lupus Abstract S1:04 Table 1 Pooled safety data from WILLOW cohorts A and B for participants with CLE/SLE and cutaneous manifestations a Lupus Science & Medicine: first published as 10.